Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $237,928,239 across 11 holdings for the quarter ended 2022-12-31, in a 13F-HR filed 2023-02-14. Its ten largest share positions make up 98.62% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001567619-23-002883

Period
2022-12-31
Reported value
$238M
Holdings
11
Top 10 weight
98.62%
New
0
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BIORA THERAPEUTICS INCadded+12,506,250$1.65M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q4 2022

Share positions as resolved from 13F-HR 0001567619-23-002883, largest first. % of portfolio is the value over $237,928,239, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AMRYT PHARMA LTD - SPNR ADRAMRYT PHARMA LTD - SPNR ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 8,857,268 shares 8,857,268$64.7M27.18%0
RVLPQRVL PHARMACEUTICALS PLC ORDINAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 14,600,444 shares 14,600,444$16.4M6.87%0Timeline
CAREMAX INCCAREMAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 4,467,219 shares 4,467,219$16.3M6.85%0
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,792,114 shares 1,792,114$7.58M3.19%0Timeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 42,362,097 shares 42,362,097$5.58M2.34%+12,506,250
SOCIETAL CDMO INCSOCIETAL CDMO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 2,202,420 shares 2,202,420$3.28M1.38%0

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC NOTE 7.250%12/0principal103,500,000$56.3M0
OMEROS CORPOMEROS CORP NOTE 5.250% 2/1principal58,131,000$31.7M+17,981,000
Omeros CorpOmeros Corp NOTE 6.250%11/1principal21,005,000$20.2M0
PARATEK PHARMACEUTICALS INCPARATEK PHARMACEUTICALS INC Convertible Bondprincipal9,000,000$8.21M0
BRIDGEBIO PHARMA INCBRIDGEBIO PHARMA INC Convertibleprincipal20,000,000$7.75M0

How Q4 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001567619-23-002883 base2023-02-14acceptance time not in the bulk data set